KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to -$5.8 million.

  • Biocryst Pharmaceuticals' Cash from Financing Activities fell 75.90% to $87,000 in Q4 2015 from the same period last year, while for Dec 2015 it was $5.5 million, marking a year-over-year decrease of 95.10%. This contributed to the annual value of -$5.8 million for FY2024, which is 117.73% down from last year.
  • Per Biocryst Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$5.8 million for FY2024, which was down 117.73% from $32.5 million recorded in FY2023.
  • In the past 5 years, Biocryst Pharmaceuticals' Cash from Financing Activities registered a high of $359.7 million during FY2021, and its lowest value of -$5.8 million during FY2024.
  • In the last 3 years, Biocryst Pharmaceuticals' Cash from Financing Activities had a median value of $32.5 million in 2023 and averaged $38.3 million.
  • Per our database at Business Quant, Biocryst Pharmaceuticals' Cash from Financing Activities surged by 203.32% in 2020 and then tumbled by 117.73% in 2024.
  • Biocryst Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $300.6 million in 2020, then increased by 19.65% to $359.7 million in 2021, then tumbled by 75.53% to $88.0 million in 2022, then tumbled by 63.10% to $32.5 million in 2023, then crashed by 117.73% to -$5.8 million in 2024.